Jay R. Luly

2020

In 2020, Jay R. Luly earned a total compensation of $5.2M as President and Chief Executive Officer at Enanta Pharmaceuticals, a 16% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$415,716
Option Awards$3,598,848
Salary$667,063
Stock Awards$497,039
Other$19,171
Total$5,197,837

Luly received $3.6M in option awards, accounting for 69% of the total pay in 2020.

Luly also received $415.7K in non-equity incentive plan, $667.1K in salary, $497K in stock awards and $19.2K in other compensation.

Rankings

In 2020, Jay R. Luly's compensation ranked 2,110th out of 13,090 executives tracked by ExecPay. In other words, Luly earned more than 83.9% of executives.

ClassificationRankingPercentile
All
2,110
out of 13,090
84th
Division
Manufacturing
808
out of 5,617
86th
Major group
Chemicals And Allied Products
288
out of 2,248
87th
Industry group
Drugs
244
out of 1,948
88th
Industry
Pharmaceutical Preparations
173
out of 1,453
88th

Pay ratio

Jay R. Luly's Pay$5,197,837
Median Employee's Pay$232,629
Pay Ratio

22

to 1

In 2020, the annual total compensation of Jay R. Luly was $5,197,837.

The annual total compensation of the median employee at Enanta Pharmaceuticals was $232,629.

The ratio of Jay R. Luly's pay to the pay of median employee was therefore 22 to one.

Source: SEC filing on January 21, 2021.

Luly's colleagues

We found four more compensation records of executives who worked with Jay R. Luly at Enanta Pharmaceuticals in 2020.

2020

Yat Or

Enanta Pharmaceuticals

Chief Scientific Officer

2020

Nathalie Adda

Enanta Pharmaceuticals

Chief Medical Officer

2020

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

2020

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

News

In-depth

You may also like